Pages that link to "Q34750568"
Jump to navigation
Jump to search
The following pages link to A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines (Q34750568):
Displaying 20 items.
- Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens (Q26774913) (← links)
- Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms (Q27692033) (← links)
- The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential (Q28075927) (← links)
- Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells (Q28487347) (← links)
- Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms (Q31077729) (← links)
- Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. (Q33634389) (← links)
- Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell (Q33741100) (← links)
- Implications of heterogeneity in multiple myeloma (Q33914824) (← links)
- Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. (Q34345502) (← links)
- Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma (Q34364560) (← links)
- Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. (Q34786411) (← links)
- A novel measure of chromosome instability can account for prognostic difference in multiple myeloma (Q34805291) (← links)
- In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells (Q35167162) (← links)
- RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. (Q35187880) (← links)
- Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma (Q35321868) (← links)
- Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway (Q35604566) (← links)
- Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma (Q35944699) (← links)
- European perspective on multiple myeloma treatment strategies: update following recent congresses (Q35989943) (← links)
- Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy (Q36010195) (← links)
- Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma (Q36413655) (← links)